<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927511</url>
  </required_header>
  <id_info>
    <org_study_id>FIDeS</org_study_id>
    <nct_id>NCT00927511</nct_id>
  </id_info>
  <brief_title>A Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC)</brief_title>
  <acronym>FIDeS</acronym>
  <official_title>A Phase II Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC) (Fulvestrant Intensity Density Study - Studio FIDeS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regina Elena Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regina Elena Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In post-menopausal metastatic hormone-responsive breast cancer women.&#xD;
&#xD;
      This study is a two arm randomized trial to evaluate the effectiveness of dose-titration&#xD;
      regimen of fulvestrant compared with the approved dosing regimen. Patients will be randomized&#xD;
      to one of the following treatment arms:&#xD;
&#xD;
      Arm A: Fulvestrant 500 mg days 0, 14, 28, then 250 mg every 2 weeks for 5 administrations,&#xD;
      then 250 mg every 28 days, until progression or unacceptable toxicity Arm B: Fulvestrant 250&#xD;
      mg every 28 days until progression or unacceptable toxicity&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Arm A: Fulvestrant 500 mg days 0, 14, 28, then 250 mg every 2 weeks for 5 administrations,&#xD;
      then 250 mg every 28 days, until progression or unacceptable toxicity Arm B: Fulvestrant 250&#xD;
      mg every 28 days until progression or unacceptable toxicity&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">April 2012</completion_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression (sec. RECIST) or death from any cause; where there is no evidence of progression, TTP will be right-censored at last patients contact where status was recorded</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A - Dose Tritation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fulvestrant 500 mg days 0, 14, 28, then 250 mg every 2 weeks for 5 administrations, then 250 mg every 28 days, until progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B- Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fulvestrant 250 mg every 28 days until progression or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Fulvestrant 500 mg days 0, 14, 28, then 250 mg every 2 weeks for 5 administrations, then 250 mg every 28 days, until progression or unacceptable toxicity vs Fulvestrant 250 mg every 28 days until progression or unacceptable toxicity</description>
    <arm_group_label>A - Dose Tritation</arm_group_label>
    <arm_group_label>B- Control</arm_group_label>
    <other_name>Faslodex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Histological or cytological diagnosis of hormone-responsive metastatic breast cancer&#xD;
&#xD;
          -  Documented positive hormone receptor status (ER+ve and/or PgR+ve) of primary or&#xD;
             metastatic tumor issue, according to the local laboratory parameters&#xD;
&#xD;
          -  Postmenopausal women, defined as a woman fulfilling any 1 of the following criteria:&#xD;
&#xD;
          -  Age ≥ 60 years&#xD;
&#xD;
          -  Age ≥ 45 years with amenorrhoea ≥ 12 months with an intact uterus&#xD;
&#xD;
          -  Having undergone a bilateral oophorectomy&#xD;
&#xD;
          -  FSH and oestradiol levels in postmenopausal range (utilizing ranges from the local&#xD;
             laboratory facility)*&#xD;
&#xD;
             *In patients who have previously been treated with a monthly LH-RH analogue, the last&#xD;
             depot must have been administered more than 13 months (or 15 months in case of&#xD;
             3-monthly LH-RH analogue) prior to randomization, and menses must not have restarted&#xD;
&#xD;
          -  Prior hormonal treatment in adjuvant setting is allowed&#xD;
&#xD;
          -  No more than one prior hormonal treatment for metastatic disease&#xD;
&#xD;
          -  Patients with HER2 positive disease in treatment with specific anti-HER2 therapy&#xD;
             (trastuzumab, lapatinib) are allowed&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Patients fulfilling one of the following criteria:&#xD;
&#xD;
          -  Patients with measurable disease as per RECIST criteria. This is defined as at least&#xD;
             one lesion that can be accurately measured in at least one dimension (longest diameter&#xD;
             to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT&#xD;
             scan&#xD;
&#xD;
          -  Patients with bone lesions, lytic or mixed (lytic + sclerotic), in the absence of&#xD;
             measurable disease as defined by RECIST criteria. Bone lesions must be evaluable by&#xD;
             plain X-ray, CT or MRI. Patients with lesions identified only on radionucleotide bone&#xD;
             scan are not eligible&#xD;
&#xD;
          -  Patients with a history of other malignancies are eligible if they have been&#xD;
             disease-free for at least 5 years and are deemed by the investigator to be at low risk&#xD;
             for recurrence. Patients with the following cancers are eligible if diagnosed and&#xD;
             treated within the past 5 years: cervical carcinoma in situ, melanoma in situ, and&#xD;
             basal cell or squamous cell carcinoma of the skin&#xD;
&#xD;
          -  Patients must have normal organ function as defined below:&#xD;
&#xD;
          -  total bilirubin within normal institutional limits&#xD;
&#xD;
          -  AST (SGOT)/ALT(SGPT) 2.5 X institutional upper limit of normal&#xD;
&#xD;
          -  creatinine within normal institutional limits or creatinine clearance 0.60 mL/min/1.73&#xD;
             m2 for patients with creatinine levels above institutional normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receive concurrent treatment with an investigational agent or participate in another&#xD;
             clinical trial&#xD;
&#xD;
          -  Have a concurrent disease or condition that would make the patient inappropriate for&#xD;
             study participation, or any serious medical disorder that would interfere with the&#xD;
             patient safety&#xD;
&#xD;
          -  Patients with responsive or stable disease after chemotherapy (fulvestrant&#xD;
             administration in not allowed as maintenance therapy)&#xD;
&#xD;
          -  More than 1 line of chemotherapy in metastatic setting; more than 1 maintenance&#xD;
             hormonal therapy&#xD;
&#xD;
          -  Life expectancy &lt; 6 months&#xD;
&#xD;
          -  Have an active or uncontrolled infection&#xD;
&#xD;
          -  Have dementia, altered mental status, or any psychiatric condition that would prohibit&#xD;
             the understanding or rendering of informed consent&#xD;
&#xD;
          -  History of bleeding diathesis, or long term anticoagulant therapy (other than&#xD;
             antiplatelet therapy and low dose warfarin)&#xD;
&#xD;
          -  History of hypersensitivity to active or inactive excipients of Fulvestrant&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paola Papaldo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regina Elena Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Papaldo Paola, MD</last_name>
    <phone>06-52666230</phone>
    <email>p.papaldo@mclink.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giannarelli Diana, MS</last_name>
    <email>giannarelli@ifo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Regina Elena Cancer Institute</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Papaldo Paola, MD</last_name>
      <phone>06-52666230</phone>
      <email>p.papaldo@mclink.it</email>
    </contact>
    <investigator>
      <last_name>Papaldo Paola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>June 24, 2009</study_first_submitted>
  <study_first_submitted_qc>June 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <last_update_submitted>July 21, 2011</last_update_submitted>
  <last_update_submitted_qc>July 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Paola Papaldo</name_title>
    <organization>Regina Elena Cancer Institute</organization>
  </responsible_party>
  <keyword>metastatic hormone-responsive breast cancer menopausal women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

